Ulcerative Colitis Clinical Trial
Official title:
Reduction in Length of Hospitalization in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy With Infliximab by the Use of Web-app Constant-Care. One Year Follow-up, Inclusive Colectomy Rate.
The primary aim is to evaluate if introduction of eHealth in its form of the web application
Constant-Care (https://ibd.constant-care.com) could reduce the length of hospitalization in
patients with acute severe Ulcerative Colitis treated with infliximab. This is relative to
historical controls extracted from medical records.
Patients will self-measure on the web-application while hospitalized as well as after
discharge. At the web-application different questionnaires are filled out and a fecal
calprotectin (FC) analysis is performed on a smartphone. The final follow up is one year
after admission.
Consecutive inclusion of patients hospitalized at North Zealand University Hospital (NOH) in
Denmark between December 2019 and June 2020 with the diagnosis acute severe Ulcerative
Colitis (UC) (expected 14-28 patients). The included patients will be matched with historical
controls 1:3 (matched on age and sex). Controls will be extracted from medical records
(2015-2019). Only historical controls who meet the inclusion criteria as well as receive
Infliximab rescue therapy, when admitted to hospital due to the diagnosis acute severe UC,
are included. This means that patients, who are responders to high dose glucocorticoids are
excluded as historical controls.
At Day 0 all the included UC patients will receive an introduction and their own personal
login to the Constant-Care (CC) web-application (Two Factor Authentication) as well as
receive standard treatment with IV glucocorticoids. When the patients have received an
introduction to CC, they will register their disease activity; Simple Clinical Colitis
Activity index (SCCAI). This tool captures the patient's illness experience (Patient-Reported
Outcomes, PROs). Furthermore, the patients are introduced and assisted with Fecal
Calprotectin (FC) testing kit (CalproSmart). For this analysis, patients will receive a
personal login to CalproSmart.
Beside the CC monitoring initiated at Day 0, the patient will be followed through standard
monitoring (DSGH guidelines) such as vital parameters daily (minimum three times a day),
conventional FC Elisa (send to Hvidovre), blood samples and the frequency of bowel movements.
In addition, fecal samples will be collected from all patients to microbiome analysis for
future use (I Suite nr: 03719, ID no: NOH-2015-017). A separate written informed consent is
collected when patient want to participate in future research with microbiome analysis.
Furthermore, the patients' medical history, disease course and Montreal classification will
be examined. At follow-up (week 52) it is considered if the patient had a colectomy.
While hospitalized patients register in CC everyday as well as perform the FC test with
CalproSmart. This is continued until discharge or whenever the patient is categorized as
"green". A patient is classified as "green" when either SCCAI or FC are in the green zone
(cut-off values: SCCAI; ≤ 2 (green), > 2 - 5 (yellow) and > 5 (red), FC; ≤ 200 mg/kg (green),
201-600 mg/kg (yellow), > 600 (red)).
On or around Day 3 it is considered if patient is a responder to the initial treatment with
glucocorticoids. In case only partial or no response is observed the patient is considered
rescue therapy (Infliximab, IFX) if no contraindications are present. This divides the
patients in two arms; responders and partial/non-responders.
Both groups will continue daily registration in CC and perform FC test while admitted to
hospital or until classified as "green". After discharge the responder group will register in
CC and perform FC on demand in case of relapse in disease. At follow up (week 52) responders
will register in CC and perform the FC test.
Partial/non-responders will, after discharge, register in CC and perform FC test once every
week in the following 7 weeks. Afterwards registration is done on demand in case of relapse
in disease. A final registration in CC and FC test is done at follow up.
In CC, patients will register: SCCAI, S-IBDQ, WEB-DI and FC via CalproSmart.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |